Was wondering if we were going to see the entire report ...
" Conclusions The results of this study demonstrate that the investigational wearable injector may be useful for subcutaneous administration of larger drug volumes. The delivery of 3 mL of saline in abdominal subcutaneous tissue was well tolerated by all subjects and only resulted in minor discomfort. The devices were easy to use, reliable, and there were no adverse events. Future studies will determine whether the Unilife investigational device design is adequate for patient use with active drug treatment."
Lets see if that holds up when the actual clinical trials report out ...
UNS Price at posting:
5.5¢ Sentiment: Buy Disclosure: Held
